As Congress debates how to lower prescription drug costs, a large majority of Americans want the federal government to negotiate with drug makers to reduce prices paid by Medicare, according to a new poll by the Kaiser Family Foundation.

Specifically, 88% of those queried support negotiations to lower Medicare Part D costs, and 85% believe this approach should be pursued for both Medicare and private insurers. The responses included large majorities of Democrats, Republicans, and independents. Moreover, 72% support increasing taxes on drug makers that refuse to negotiate with the government; 69% of Republicans agreed with this idea.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Note that the survey asked about “lower prices” (whatever that means), not lower costs or lower spending.

    Oddly, Kaiser never seems to get around asking about lowering prices for the 85% of non-drug U.S. healthcare spending. I wonder why …

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy